Michele Guida
Istituto Tumori Bari(IT)Istituti di Ricovero e Cura a Carattere Scientifico(IT)
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Cutaneous Melanoma Detection and Management, Immunotherapy and Immune Responses
Most-Cited Works
- → A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma(2011)531 cited
- → Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial(2018)212 cited
- → Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial(2022)209 cited
- → Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis(2016)184 cited
- → Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study(2001)168 cited
- → Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort